Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90% in the pediatric population
An oral presentation at ISPPD highlighted an approximately 9 to 15-fold higher serotype 3 immunogenicity response after Dose 3 and 4 in infants receiving Pfizer’s 25-valent vaccine candidate (25vPnC) compared to PREVNAR 20®
The investigational vaccine candidate was well-tolerated with no safety concerns identified in a Phase 2 study
Based on these encouraging results from the Phase 2 program across serotypes and discussions with regulatory authorities, Pfizer initiated its Phase 3 25vPnC pediatric program
